Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation
Preventing Moderate to Severe Dermatologic Adverse Events in First-Line EGFR-Mutant Advanced NSCLC Treated With Amivantamab Plus Lazertinib: Early Success of the COCOON Trial
Alexander Spira, MD, PhD, FACP, FASCO, and Randi Rabin, MPH, MSc, PA-C, discuss how proactive dermatologic adverse event management—specifically through the COCOON protocol—enhances treatment adherence, reduces toxicity, and improves quality of life for patients with EGFR-mutant non–small cell lung cancer receiving amivantamab plus lazertinib.
| WATCH NOW |
Featured Video
| Building Support Systems: Resources and Multidisciplinary Collaboration for Optimizing COCOON Implementation Panelists discuss how keeping management of dermatologic adverse effects “in-house” with oncology teams is often preferable to referring patients to dermatologists, though some patients occasionally benefit from specialized care for nail issues.
|